Lurbinectedin Plus Doxorubicin Shows Early Efficacy and Safety in Soft Tissue Sarcomas
A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.
Source: onclive.com